"The primary objective was to evaluate the difference in urinary MeNAM levels between placebo and NIAGEN (100 mg, 300 mg, and 1000 mg) after 8 weeks of supplementation.
The secondary objectives were to:
- evaluate the rate of increase in urinary MeNAM levels between placebo and NIAGEN (100 mg, 300 mg, and 1000 mg) after 8 weeks of supplementation
- the difference and rate of increase in other NR metabolites levels in blood between placebo and NIAGEN (100 mg, 300 mg, and 1000 mg) after 8 weeks of supplementation
- the difference and rate of increase in other NR metabolites levels in urine between placebo and NIAGEN (100 mg, 300 mg, and 1000 mg) after 8 weeks of supplementation
- the difference in other NR metabolites levels in muscle between placebo and NIAGEN (100 mg, 300 mg, and 1000 mg) after 8 weeks of supplementation.
Exploratory outcomes included:
- exploring the changes in Resting Energy Expenditure (REE) relative to placebo after 8 weeks of supplementation
- the changes in blood levels of branched-chain amino acids relative to placebo after 8 weeks of supplementation
- the changes in blood levels of high sensitivity C-reactive protein (hsCRP) relative to placebo after 8 weeks of supplementation.
The safety objectives included the difference in vital signs, hematology and clinical chemistry parameters including high density lipoprotein cholesterol (HDL-C), LDL-C, triglycerides, and total cholesterol between the placebo- and NIAGEN-treated groups, and the difference in the incidence of adverse events between the placebo- and NIAGEN-treated groups.
The effect of NIAGEN on plasma HCY levels was determined as a post hoc analysis."